New Delhi, Jan. 30 -- Laurus Labs Ltd. shares jumped by up to 10 per cent on Thursday, January 30, following the U.S. approval of an "emergency humanitarian waiver" that ensures continued access to U.S.-funded HIV treatment across 55 countries.

The stock declined by more than 15 per cent on Monday following the U.S. government's directive to halt the President's Emergency Plan for AIDS Relief (PEPFAR), which would have disrupted the supply of antiviral medications for millions.

On January 28, U.S. Secretary of State Marco Rubio issued a temporary waiver on the pause of "life-saving humanitarian assistance," including the PEPFAR program. However, the waiver excluded services related to abortion, gender, diversity, transgender issues, and...